The three-year collaboration includes $1.5 million for chronic kidney disease research.
After almost a year of negotiations, Baxter has reached a $4 billion deal for Swedish firm Gambro AB as it makes a play for the kidney dialysis market.
Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.